Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Atypon full text link Atypon Free PMC article
Full text links

Actions

Share

Review
.2012 May;28(5):400-8.
doi: 10.3109/09513590.2012.662547. Epub 2012 Apr 2.

An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest

Affiliations
Free PMC article
Review

An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest

Franca Fruzzetti et al. Gynecol Endocrinol.2012 May.
Free PMC article

Abstract

Natural estrogens such as estradiol (E(2)) or its valerate ester (E(2)V) offer an alternative to ethinyl estradiol (EE). E(2)-containing combined oral contraceptives (COCs) have demonstrated sufficient ovulation inhibition and acceptable contraceptive efficacy. However, earlier formulations were generally associated with unacceptable bleeding profiles. Two E(2)V-containing preparations have been approved to date for contraceptive use: E(2)V/cyproterone acetate (CPA) (Femilar(®); only approved in Finland and only in women >40 years or women aged 35-40 years in whom a COC containing EE is not appropriate) and E(2)V/dienogest (DNG; Qlaira(®)/Natazia(®)). The objective of the current review is to provide an overview of the development of COCs containing natural estrogen, highlighting past issues and challenges faced by earlier formulations, as well as the current status and future directions. The majority of information to date pertains to the development of E(2)V/DNG.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean serum estradiol (E2) concentration over 24 h following oral administration of estradiol valerate (E2V)/dienogest (DNG) [17]. Zeun S, et al., Eur J Contracept Reprod Health Care, 2009;14(3):221–32, copyright© 2009, Informa Healthcare. Reproduced with permission of Informa Healthcare.
Figure 2
Figure 2
Mean ethinyl estradiol (EE) concentration over 24 hours following oral administration of EE 20 μg/levonorgestrel (LNG) 100 μg [18]. Endrikat J, et al., Eur J Contracept Reprod Health Care, 2002;7(2):79–90, copyright© 2002, Informa Healthcare. Reproduced with permission of Informa Healthcare.
Figure 3
Figure 3
Dosing regimen of an estradiol valerate (E2V)/dienogest (DNG)-containing oral contraceptive administered using an estrogen step-down and progestogen step-up approach over a 28-day treatment cycle (with 26 days of active tablets). Numbers along the bottom of the figure correspond to days of the 28-day cycle.
Figure 4
Figure 4
Minimum mean (standard deviation [SD]) serum concentrations of estradiol during daily administration of a 28-day oral contraceptive containing estradiol valerate (E2V)/dienogest (DNG) [50].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lobo RA, Stanczyk FZ. New knowledge in the physiology of hormonal contraceptives. Am J Obstet Gynecol. 1994;170:1499–1507. - PubMed
    1. Düsterberg B, Ellman H, Müller U, Rowe E, Mühe B. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene. Gynecol Endocrinol. 1996;10:33–39. - PubMed
    1. Huber J, Foidart JM, Wuttke W, Merki-Feld GS, The HS, Gerlinger C, Schellschmidt I, Heithecker R. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care. 2000;5:25–34. - PubMed
    1. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update. 2006;12:169–178. - PubMed
    1. Spona J, Feichtinger W, Kindermann C, Moore C, Mellinger U, Walter F, Gräser T. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mgdienogest. Contraception. 1997;56:185–191. - PubMed

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full text links
Atypon full text link Atypon Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp